이스라엘 - 영어 - Ministry of Health

medomie pharma ltd, israel - hydrocortisone - granules in capsules for opening - hydrocortisone 0.5 mg - hydrocortisone - alkindi is indicated for replacement therapy of adrenal insufficiency in infants, children and adolescents (from birth to < 18 years old)

이스라엘 - 영어 - Ministry of Health

medomie pharma ltd, israel - hydrocortisone - granules in capsules for opening - hydrocortisone 1 mg - hydrocortisone - alkindi is indicated for replacement therapy of adrenal insufficiency in infants, children and adolescents (from birth to < 18 years old)

이스라엘 - 영어 - Ministry of Health

medomie pharma ltd, israel - hydrocortisone - granules in capsules for opening - hydrocortisone 2 mg - hydrocortisone - alkindi is indicated for replacement therapy of adrenal insufficiency in infants, children and adolescents (from birth to < 18 years old)

이스라엘 - 영어 - Ministry of Health

medomie pharma ltd, israel - hydrocortisone - granules in capsules for opening - hydrocortisone 5 mg - hydrocortisone - alkindi is indicated for replacement therapy of adrenal insufficiency in infants, children and adolescents (from birth to < 18 years old)

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

south eastern sydney local health district - skin, quantity: 1 u - graft - excipient ingredients: glycerol - skin - repair, replacement and regeneration of lost ordamaged skin

유럽 연합 - 영어 - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastic agents - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy.brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

이스라엘 - 영어 - Ministry of Health

megapharm ltd - aldesleukin - powder for solution for infusion - aldesleukin 18 miu - aldesleukin - proleukin (aldesleukin) is indicated for the treatment of adults with metastatic renal cell carcinoma (metastatic rcc). proleukin is indicated for the treatment of adults with metastatic melanoma.careful patient selection is mandatory prior to the administration of proleukin.

유럽 연합 - 영어 - EMA (European Medicines Agency)

eigerbio europe limited - lonafarnib - progeria; laminopathies - other alimentary tract and metabolism products, - zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of hutchinson-gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous lmna mutation with progerin-like protein accumulation or a homozygous or compound heterozygous zmpste24 mutation.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - interferon gamma-1b, quantity: 4 million iu/ml - injection, solution - excipient ingredients: succinic acid; sodium succinate hexahydrate; mannitol; water for injections; polysorbate 20 - as an adjunct for reduction of the frequency of serious infections in patients with chronic granulomatous disease (cgd). the benefits of imukin have been most marked in children with cgd although imukin may be used in adult patients.

이스라엘 - 영어 - Ministry of Health

medison pharma ltd - zanubrutinib - capsules - zanubrutinib 80 mg - • brukinsa is indicated for the treatment of adult patients with mantle cell lymphoma (mcl) who have received at least one prior therapy.• brukinsa is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm).• brukinsa is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (mzl) who have received at least one anti-cd20-based regimen.• brukinsa is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll).